Corporate Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, has demonstrated encouraging activity and tolerability in early clinical testing for folate receptor α-positive ovarian cancer and is progressing to advanced clinical testing. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. 

NASDAQ: IMGN
$6.11 - 0.50
May 3, 2016 at 4:00 PM ET
Intraday data provided by eSignal


Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com

 

Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402
E-mail: shareholder@broadridge.com

 

Independent Accountants

Ernst & Young LLP
Boston, MA


Receive E-mail Alerts

Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.


You are now leaving this website. If you would like to continue, click Continue.
CancelContinue